A University of Calgary study has found promising results for the generic drug hydroxychloroquine when used to treat the evolution of disability of primary progressive multiple sclerosis (MS), the ...

The US Food and Drug Administration (FDA) on Monday issued two new product-specific guidance documents for the unproven but highly demanded potential COVID-19 drugs chloroquine phosphate and ...

CALGARY, Alberta (StudyFinds.org) – Hydroxychloroquine may not be a reliable treatment for COVID-19, but a new study finds it may find a new job treating the worst form of multiple sclerosis (MS).

Please provide your email address to receive an email when new articles are posted on . Hydroxychloroquine was associated with improved kidney function for patients with lupus nephritis. Patients and ...

Early treatment with hydroxychloroquine cut the death rate significantly in certain sick patients hospitalized with COVID-19 — and without heart-related side effects, according to a new study ...

Novartis’ generic hydroxychloroquine may have little use in COVID-19, but the Swiss pharma still wants to contribute its low-cost drugs in some way in the current fight. Novartis’ Sandoz unit will ...

The new watch list from the US Food and Drug Administration (FDA) includes almost two dozen drugs or drug classes for which there is a potential sign of serious risk or new safety information. The ...